Organization
Tisch Cancer Institute
30 abstracts
Abstract
ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.Org: Exact Sciences Corporation, Genomic Health Inc, Fred Hutchinson Cancer Research Center, Tisch Cancer Institute, Fox Chase Cancer Center,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Org: Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Université Paris-Sud, Université Paris-Saclay, Netherlands Cancer Institute,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.Org: Memorial Sloan Kettering Cancer Center, Medical University of Silesia, Hematology Ward, S. Eugenio Hospital, The University of Texas MD Anderson Cancer Center,
Abstract
Impact of race/ethnicity on the MammaPrint genomic assay risk and prognosis in early breast cancer (EBC): A National Cancer Database (NCDB) analysis.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Tisch Cancer Institute, Mount Sinai Hospital-Breast Medical Oncology,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
The influence of access to care on radiation therapy utilization among older women with breast cancer.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Institute for Healthcare Delivery Science, Tisch Cancer Institute, Department of Population Health Science and Policy, Memorial Sloan Kettering Cancer Center,
Abstract
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).Org: Gustave Roussy Cancer Center, The Institute of Cancer Research/The Royal Marsden Hospital, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research, ISA Pharmaceuticals B.V., Regeneron Pharmaceuticals, Inc.,
Abstract
TTMV and association with relapse in patients with HPV related SCCHN undergoing CRT.Org: Mount Sinai Hospital-Breast Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Medical Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,
Abstract
Can TTMV clearance predict recurrence in HPV HNSCC?Org: Hematology and Medical Oncology, Universitätsklinikum Jena, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Medical Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,
Abstract
Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.Org: Washington University in St. Louis, Medical College of Georgia at Augusta University, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Second primary squamous cell cancers in the HPV de-escalation Quarterback Trials.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Otolaryngology, Head and Neck Surgery, University of Washington, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Sexual health outcomes in sexual minority vs. heterosexual men after prostate radiotherapy.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, Medical College of Wisconsin, Division of Infectious Diseases,
Abstract
Immunotherapy in stage IV non-small cell lung cancer according to racial characteristics and community of residence.Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Tisch Cancer Institute,
Abstract
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.Org: Samsung Medical Centre, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Memorial Sloan Kettering Cancer Center,
Abstract
Assessing barriers to prostate cancer clinical trial participation among Black and African Americans: A multi-perspective qualitative study.Org: David Geffen School of Medicine at UCLA, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Sandra and Edward Meyer Cancer Center, The Pennsylvania Prostate Cancer Coalition, Tisch Cancer Institute,
Abstract
Genomic and immune profiling of rare non-squamous sinonasal tumors.Org: Winship Cancer Institute, Emory University School of Medicine, Emory University, Atlanta, GA, USA, Caris Life Sciences, Irving, TX, Department of Otolaryngology Head and Neck Surgery, Emory University Hospital Midtown,
Abstract
Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 randomized controlled trials.Org: Mount Sinai Beth Israel, Mount Sinai Hospital-Breast Medical Oncology, Kyoto University Hospital, Center for Thoracic Oncology, Tisch Cancer Institute,
Abstract
Clinical outcomes and correlation with longitudinal circulating tumor (ct)DNA dynamics of a phase I/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced or metastatic breast cancer.Org: Princess Margaret Cancer Center, University Health Network, University of Toronto, The Ottawa Hospital Cancer Center, GSK Research and Development Upper Providence, Collegeville, PA,
Abstract
Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.Org: Fred Hutchinson Cancer Research Center, Seattle, WA, American Society of Clinical Oncology, Alexandria, VA, Friends of Cancer Research, Washington, DC,
Abstract
Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategies.Org: Mount Sinai Beth Israel, Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer?Org: Hematology and Medical Oncology, Universitätsklinikum Jena, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tisch Cancer Institute,
Abstract
Better together: A team-based approach to improve prior authorization efficiencies and wellness in physicians and advanced care providers.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, New York, NY,
Abstract
Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Current Health, Dorset County Hospital, NHS Foundation Trust, Tisch Cancer Institute, Mount Sinai School of Medicine,
Abstract
Non-vitamin k oral antagonists versus aspirin for primary thromboprophylaxis in patients with multiple myeloma on outpatient chemotherapy: A systematic review and meta-analysis.Org: Federal University of Ceará, Fortaleza, Brazil, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Federal University of Campina Grande, Cardiff University School of Medicine,
Abstract
Adjuvant therapy in localized vs regional biliary tract cancers: A SEER analysis.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Albert Einstein College of Medicine/Montefiore Medical Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Tisch Cancer Institute,
Abstract
Clinical outcomes of patients who are frail and elderly with unresectable pancreatic ductal adenocarcinoma (PDAC) treated with chemotherapy.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Morningside-West, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Patterns of diversity in cancer clinical trial enrollment at a New York City academic health system, 2018-2022.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Tisch Cancer Institute,